Suppr超能文献

发展中国家的抗菌药物耐药性威胁:成因与控制策略

The threat of antimicrobial resistance in developing countries: causes and control strategies.

作者信息

Ayukekbong James A, Ntemgwa Michel, Atabe Andrew N

机构信息

Section for Clinical Microbiology, Redeem Biomedical, P.O. Box 16, Buea, Cameroon.

Metabiota Inc., Nanaimo, BC Canada.

出版信息

Antimicrob Resist Infect Control. 2017 May 15;6:47. doi: 10.1186/s13756-017-0208-x. eCollection 2017.

Abstract

The causes of antimicrobial resistance (AMR) in developing countries are complex and may be rooted in practices of health care professionals and patients' behavior towards the use of antimicrobials as well as supply chains of antimicrobials in the population. Some of these factors may include inappropriate prescription practices, inadequate patient education, limited diagnostic facilities, unauthorized sale of antimicrobials, lack of appropriate functioning drug regulatory mechanisms, and non-human use of antimicrobials such as in animal production. Considering that these factors in developing countries may vary from those in developed countries, intervention efforts in developing countries need to address the context and focus on the root causes specific to this part of the world. Here, we describe these health-seeking behaviors that lead to the threat of AMR and healthcare practices that drive the development of AMR in developing countries and we discuss alternatives for disease prevention as well as other treatment options worth exploring.

摘要

发展中国家抗菌药物耐药性(AMR)的成因复杂,可能源于医疗保健专业人员的行为、患者对抗菌药物使用的行为,以及人群中抗菌药物的供应链。其中一些因素可能包括不适当的处方行为、患者教育不足、诊断设施有限、抗菌药物的非法销售、缺乏适当运作的药品监管机制,以及抗菌药物在动物生产等非人类用途中的使用。鉴于发展中国家的这些因素可能与发达国家不同,发展中国家的干预措施需要针对具体情况,关注世界这一地区特有的根本原因。在此,我们描述了导致AMR威胁的这些就医行为以及在发展中国家推动AMR发展的医疗实践,并讨论了疾病预防的替代方法以及其他值得探索的治疗选择。

相似文献

1
The threat of antimicrobial resistance in developing countries: causes and control strategies.
Antimicrob Resist Infect Control. 2017 May 15;6:47. doi: 10.1186/s13756-017-0208-x. eCollection 2017.
2
Non-prescription sales of antimicrobial agents at community pharmacies in developing countries: a systematic review.
Int J Antimicrob Agents. 2018 Dec;52(6):771-782. doi: 10.1016/j.ijantimicag.2018.09.022. Epub 2018 Oct 9.
3
The role of Environmental Health in preventing antimicrobial resistance in low- and middle-income countries.
Environ Health Prev Med. 2021 Oct 5;26(1):100. doi: 10.1186/s12199-021-01023-2.
4
Antimicrobial self medication in patients attending a sexually transmitted diseases clinic.
Int J STD AIDS. 1997 Jul;8(7):456-8. doi: 10.1258/0956462971920343.
6
Drivers of inappropriate antibiotic use in low- and middle-income countries.
JAC Antimicrob Resist. 2023 May 31;5(3):dlad062. doi: 10.1093/jacamr/dlad062. eCollection 2023 Jun.
7
Waking Up to Antibiotic Resistance.
J Pharm Bioallied Sci. 2023 Jul;15(Suppl 2):S840-S842. doi: 10.4103/jpbs.jpbs_240_23. Epub 2023 Jul 11.
8
Shortage of essential antimicrobials: a major challenge to global health security.
BMJ Glob Health. 2021 Nov;6(11). doi: 10.1136/bmjgh-2021-006961.

引用本文的文献

1
One health approach unravels worrying antimicrobial resistance patterns: A cross-sectional study in Kisii, Kenya.
PLoS One. 2025 Sep 3;20(9):e0331389. doi: 10.1371/journal.pone.0331389. eCollection 2025.
9
Utilisation of antibiotics in a community pharmacy: A case from north-west, South Africa.
Afr J Prim Health Care Fam Med. 2025 Jul 23;17(1):e1-e9. doi: 10.4102/phcfm.v17i1.4943.

本文引用的文献

2
Lack of new antiinfective agents: Passing into the pre-antibiotic age?
World J Biol Chem. 2015 Aug 26;6(3):71-7. doi: 10.4331/wjbc.v6.i3.71.
3
Evaluation of antibiotic prescription in the Lebanese community: a pilot study.
Infect Ecol Epidemiol. 2015 Jun 24;5:27094. doi: 10.3402/iee.v5.27094. eCollection 2015.
5
Multidrug-resistant pathogens in the food supply.
Foodborne Pathog Dis. 2015 Apr;12(4):261-79. doi: 10.1089/fpd.2014.1865. Epub 2015 Jan 26.
6
Contagious diseases in the United States from 1888 to the present.
N Engl J Med. 2013 Nov 28;369(22):2152-8. doi: 10.1056/NEJMms1215400.
7
Antibiotic resistance-the need for global solutions.
Lancet Infect Dis. 2013 Dec;13(12):1057-98. doi: 10.1016/S1473-3099(13)70318-9. Epub 2013 Nov 17.
8
Fecal microbiota transplantation: indications, methods, evidence, and future directions.
Curr Gastroenterol Rep. 2013 Aug;15(8):337. doi: 10.1007/s11894-013-0337-1.
9
Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease?
Best Pract Res Clin Gastroenterol. 2013 Feb;27(1):127-37. doi: 10.1016/j.bpg.2013.03.003.
10
Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile infection.
Expert Rev Anti Infect Ther. 2013 May;11(5):447-9. doi: 10.1586/eri.13.26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验